×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | fda | hydroxychloroquine | plaquenil | novartis | research

FDA Allows Swiss Firm to Test Hydroxychloroquine

pharmacist with a face mask shows a box of hydroxychloroquine with brand name Plaquenil
A pharmacist shows a box of antimalarial tablets called Plaquenil, a brand of hydroxychloroquine. (Damien Meyer/Getty Images)

By    |   Monday, 20 April 2020 08:52 AM

The U.S. Food and Drug Administration and Novartis have reached an agreement to permit the Swiss company to go ahead with a clinical trial of the anti-malaria drug hydroxychloroquine for those who have contracted the coronavirus, The Hill reported on Monday.

Novartis announced it will start enrollment for the third phase of the clinical trial for some 440 patients within the next few weeks and that the study will be carried out in more than a dozen labs across the United States.

“We recognize the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with COVID-19 disease,” said John Tsai, Novartis' chief medical officer and head of the company’s global drug development. “We mobilized quickly to address this question in a randomized, double-blind, placebo-controlled study.”

The Swiss pharmaceutical firm added that it is committed to reporting results as soon as possible.

In recent weeks President Donald Trump has repeatedly promoted hydroxychloroquine, even as top health officials on the White House coronavirus task force emphasized there is no scientific evidence the drug is effective in treating coronavirus, for which there is no cure.

Novartis said the clinical trial follows up on its commitment to donate up to 130 million tablets of hydroxychloroquine to supply worldwide clinical research efforts if the medicine is proven beneficial for treatment of COVID-19.

The Health and Human Services Department announced last month that it received 30 million such doses, according to The Hill.

© 2021 Newsmax. All rights reserved.


US
The U.S. Food and Drug Administration and Novartis have reached an agreement to permit the Swiss company to go ahead with a clinical trial of the anti-malaria drug hydroxychloroquine for those who have contracted the coronavirus, The Hill reported...
fda, hydroxychloroquine, plaquenil, novartis, research
242
2020-52-20
Monday, 20 April 2020 08:52 AM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved